PerspectiveType 2 Diabetes

GIP: No Longer the Neglected Incretin Twin?

See allHide authors and affiliations

Science Translational Medicine  15 Sep 2010:
Vol. 2, Issue 49, pp. 49ps47
DOI: 10.1126/scitranslmed.3001027

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


In the design of therapeutics to treat type 2 diabetes, researchers have exploited the observation that oral ingestion of nutrients leads to the secretion of glucose homeostasis–regulating incretin hormones (for example, glucagon-like-peptide–1) from the gut. Here, we discuss two recent papers that suggest that the “other” incretin hormone, gastric inhibitory polypeptide (GIP), also is important in the regulation of glucose homeostasis. These findings warrant further studies to unravel the mechanism of action of GIP in β-cells of the endocrine pancreas and to evaluate the possibility of designing novel therapeutics that target both incretin hormones.


  • Citation: R. N. Kulkarni, GIP: No longer the neglected incretin twin? Sci. Transl. Med. 2, 49ps47 (2010).

View Full Text

Stay Connected to Science Translational Medicine